GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance Authors: Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra Published: 2026 ABSTRACT ABSTRACTThe global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients undergoing gastrointestinal endoscopy. Although GLP‐1RAs provide significant metabolic, cardiovascular, and hepatic benefits, their tendency to slow gastric emptying has raised concerns about retained gastric contents (RGC), procedural complications, and a greater risk of pulmonary aspiration during sedation or anesthesia. This review offers a translational narrative synthesis of mechanistic, physiological, and clinical evidence connecting GLP‐1RA therapy to changes in gastric motility and peri‐endoscopic outcomes. Data from pharmacological studies, scintigraphic evaluations, large observational cohorts, and international consensus statements are combined to guide physiology‐based procedural decisions. Evidence consistently indicates that GLP‐1RA exposure is associated with a higher incidence of RGC and more frequent procedural disruptions during upper gastrointestinal endoscopy. However, it remains uncertain whether RGC leads to clinically significant aspiration. Consistent with this, real‐world data reveal no increase in aspiration pneumonia among GLP‐1RA users undergoing colonoscopy, with reported aspiration rates of approximately 0.01%–0.05%. Likewise, during upper gastrointestinal endoscopy, only a small absolute rise in aspiration‐related events has been observed, involving fewer than 0.3% of procedures. Current guidelines favor continuing GLP‐1RA therapy alongside dietary modification, structured risk assessment, selective gastric point‐of‐care ultrasound (POCUS), and multidisciplinary communication, rather than routine cessation. Emerging prospective evidence indicates that implementing a pre‐procedural clear liquid diet, with individualized timing of weekly agents, may reduce the risk of clinically significant RGC, complementing existing dietary preparation strategies. Introduction Since 1975, the global prevalence of obesity has tripled, now affecting over 650 million adults [1]. Concurrently, type 2 diabetes mellitus (T2DM) rates continue to rise, driven by aging populations and increasing adiposity [2]. Metabolic dysfunction‐associated steatotic liver disease (MASLD), previously termed non‐alcoholic fatty liver disease (NAFLD), affects 25%–32% of the global population and up to 70% of individuals with T2DM [3, 4]. These conditions frequently necessitate evaluation for nonspecific gastrointestinal symptoms and endoscopic surveillance [5, 6, 7, 8]. GLP‐1RAs have become increasingly prevalent among patients undergoing gastrointestinal endoscopy, reflecting their expanded indications for glycemic control, weight management, cardiovascular risk reduction, and the treatment of metabolic liver disease [9]. Initially developed for glycemic control, GLP‐1RAs now play a central role in weight management and in reducing cardiovascular and hepatic risk [10, 11]. Recent meta‐analyses of randomized trials demonstrate higher rates of MASH resolution without worsening fibrosis [12]. The introduction of long‐acting, once‐weekly formulations (e.g., semaglutide 2.4 mg, tirzepatide 10–15 mg) has further expanded use into non‐diabetic populations. Consequently, an increasing number of patients present for endoscopy while receiving GLP‐1RA therapy [13, 14, 15]. GLP‐1RAs exert their effects by enhancing glucose‐dependent insulin secretion, suppressing glucagon release, modulating appetite, and delaying gastric emptying [16, 17]. Although these mechanisms are beneficial for metabolic disease, delayed gastric emptying poses a procedural challenge: endoscopy units increasingly encounter retained gastric contents and suboptimal bowel preparation, even when patients follow fasting and preparation protocols [18, 19, 20]. These concerns mainly affect procedures with direct gastric access, including esophagogastroduodenoscopy (OGD), endoscopic ultrasound (EUS), and endoscopic retrograde cholangiopancreatography (ERCP). In contrast, lower gastrointestinal endoscopy does not involve gastric instrumentation. However, it may still require deep sedation, suppression of airway reflexes, and increased intra‐abdominal pressure, which can promote gastroesophageal reflux. Importantly, patients receiving GLP‐1RAs often already carry baseline aspiration risk factors—including obesity, diabetes, obstructive sleep apnea, autonomic neuropathy, and opioid exposure—making it challenging to isolate medication‐related risk from underlying comorbidity [21, 22, 23, 24, 25]. Initial perioperative guidelines recommended withholding GLP‐1RAs before procedures. However, recent gastroenterology and anesthesia statements increasingly support continuation in selected patients, provided dietary modification, structured risk assessment, point‐of‐care gastric ultrasound, and multidisciplinary communication are implemented [26, 27, 28, 29, 30]. This narrative review synthesizes current pharmacological, physiological, and clinical evidence linking GLP‐1RA therapy to peri‐endoscopic outcomes. The review focuses explicitly on adult patients undergoing gastrointestinal endoscopy while receiving GLP‐1 receptor agonists, encompassing both upper and lower gastrointestinal procedures and various anesthetic approaches. It aims to clarify differential risk profiles across procedure types and proposes a pragmatic, physiology‐informed framework to guide peri‐procedural decision‐making in this context. Methods A narrative review was conducted of studies published from January 2000 to March 2026 in PubMed, Embase, and Google Scholar. Search terms included “GLP‐1 receptor agonist,” “gastric emptying,” “retained gastric contents,” “aspiration,” “endoscopy,” “sedation,” and “anesthesia.” Additional references were identified from guidelines and article reference lists. Studies relevant to gastrointestinal endoscopy and peri‐procedural care were included. This study adopts a narrative review approach to integrate and synthesize a broad spectrum of evidence from diverse sources, which is particularly valuable given the heterogeneity and evolving nature of research in this field. Accordingly, formal systematic review methods such as predefined inclusion or exclusion criteria, structured risk‐of‐bias assessment, and meta‐analysis were not performed, permitting a flexible and comprehensive exploration of the available literature and enabling the identification of trends, gaps, and areas requiring further research. Pharmacology of GLP‐1 Receptor Agonists and Risk A clear understanding of the pharmacology of GLP‐1 receptor agonists (GLP‐1RAs) is crucial for recognizing their peri‐procedural implications in endoscopy and anesthesia. These agents are derived from the incretin pathway and mimic endogenous glucagon‐like peptide‐1 (GLP‐1), thereby enhancing glucose‐dependent insulin secretion and reducing glucagon secretion. The physiological incretin effect—where oral glucose provokes a greater insulin response than an equivalent intravenous glucose load—is mainly mediated by two gut hormones, GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP), which together control postprandial glycemic homeostasis [31, 32]. GLP‐1 receptors are expressed beyond pancreatic tissue, including gastrointestinal smooth muscle, renal tissue, vagal afferent pathways, and central autonomic centers, including the appetite center, providing the basis for both metabolic benefits and clinically relevant gastrointestinal motility effects [33]. At the cellular level (Figure 1), GLP‐1 receptor activation stimulates adenylate cyclase, increasing intracellular cAMP and activating protein kinase A (PKA)–dependent pathways, with downstream effects on insulin granule exocytosis and β‐cell survival signaling (including CREB‐ and PI3K‐AT‐mediated pathways) [34]. These insulinotropic effects remain glucose‐dependent, thereby limiting the intrinsic risk of hypoglycemia [35]. GLP‐1 RAs enhance glucose‐dependent insulin secretion through cAMP–PKA–CREB and PI3K–AKT signaling pathways within pancreatic β‐cells, while suppressing glucagon release via α‐cell inhibition. Systemic actions include slowed gastric emptying and reduced GI motility, which are central to increased rates of retained gastric contents in patients undergoing gastroscopy. Additional effects include reduced hepatic glucose output, improved cardiovascular performance, decreased insulin resistance, and appetite suppression. DPP‐4 inhibitors prolong endogenous GLP‐1 activity but exert weaker gastric motility effects compared with GLP‐1 RAs. Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. The extent and duration of delayed gastric emptying vary with formulation, dose, and exposure period. Short‐acting agents have a more pronounced effect on solid gastric emptying, whereas long‐acting formulations may exhibit partial tachyphylaxis over time, as demonstrated in physiological studies of prolonged GLP‐1 receptor stimulation, although this attenuation appears incomplete and variable between agents [35, 36]. Nonetheless, clinically significant gastric retention occurs with both types, especially during dose escalation and in the presence of additional motility‐impairing factors (e.g., diabetic autonomic neuropathy) [37]. Structurally, GLP‐1RAs can be divided into human GLP‐1 analogs (e.g., liraglutide, semaglutide, dulaglutide) and exendin‐4–based agents (e.g., exenatide), which differ in pharmacokinetics, immunogenicity, and elimination pathways [31, 38]. Exendin‐based agents are mainly eliminated via the kidneys, whereas human analogs undergo systemic proteolysis and usually do not require renal dose adjustment [39, 40]. Oral semaglutide is unique in that it relies on an absorption enhancer and fasting conditions to achieve its bioavailability [41]. Dual incretin agonists, such as tirzepatide, exemplify the shift toward multi‐pathway metabolic modulation; however, gastrointestinal tolerability and motility effects remain relevant, particularly in the peri‐procedural setting [42, 43]. Table 1 summarizes the key pharmacokinetic features of GLP‐1RAs, which are essential considerations for peri‐procedural planning. Table 1Summary of the pharmacokinetic properties of commonly used GLP‐1.AgentMolecular classDosing frequencyHalf‐life (t½)tmaxBioavailabilityKey Pharmacokinetic notesExenatide (immediate‐release)Exendin‐4 analog (53% homology)5–10 µg twice daily~2.4 h~2.1 h65%–75%Acute, pronounced gastric emptying delay; renally cleared—avoid if CrCl < 30 mL/minExenatide (extended‐release)Exendin‐4 analog2 mg weekly~2 weeks~2 weeks~100%Smooth weekly profile; reduced renal clearance concerns compared to IR formulationLixisenatideExendin‐4 analog10–20 µg daily3–4 h~2 h~32%Strong post‐prandial glucose effect; discontinued in many regionsLiraglutideHuman GLP‐1 analog (97%)0.6–1.8 mg daily12.6–14.3 h8–12 h~55%Sustained effect on appetite and weight; modest gastric motility impact compared with short‐acting agentsDulaglutideGLP‐1 analog fused to IgG Fc fragment0.75–1.5 mg weekly4.7–5.5 days~48 h~65%Low peak–trough variability; minimal renal eliminationSemaglutide (subcutaneous)Modified GLP‐1 analog (94%)0.25–1 mg weekly (up to 2.4 mg for obesity)165 h (~7 days)24–72 h~89%Very long half‐life; predictable weekly profile; attenuated gastric emptying effect with chronic useSemaglutide (oral)Modified GLP‐1 analog + SNAC absorption enhancer3–14 mg daily~6 days0.8–1.75 h~0.8%Absorption drastically reduced by food/water; must be taken fasting; faster Tmax than SC formulationTirzepatideDual GIP/GLP‐1 RA2.5–15 mg weekly105–124 h24–48 hNot applicableSynergistic incretin agonism; potent metabolic effects; attenuated gastric stasis over timeRetatrutide (investigational)Triple GLP‐1/GIP/Glucagon RAWeekly (Phase 3 trials)PendingPendingPendingUnprecedented weight‐loss effect; GI side‐effects common; not yet approvedAbbreviations: GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; SNAC, Salcaprozate sodium.John Wiley & Sons, Ltd. Summary of the pharmacokinetic properties of commonly used GLP‐1. Abbreviations: GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; SNAC, Salcaprozate sodium. These pharmacokinetic parameters are crucial for determining whether a drug should be stopped before a procedure. Once‐weekly agents, such as dulaglutide and tirzepatide, have half‐lives of about 5 days, whereas semaglutide has a half‐life of about 7 days [31, 32]. When a single weekly dose is missed, and the procedure is scheduled for the following week, plasma drug levels usually decrease by 50% or less [32]. In comparison, daily agents such as liraglutide (half‐life approximately 13 h) and exenatide immediate‐release (half‐life approximately 2.4 h) show greater reductions in plasma levels when discontinued 24 h before a procedure [22]. Therefore, withholding long‐acting agents before a procedure is unlikely to fully restore normal gastric emptying by that time; however, combining this with proper dietary preparation and fasting can significantly reduce the risk of clinically relevant residual gastric volume. GLP‐1RA Effects on Gastrointestinal Physiology GLP‐1 receptor agonists primarily delay gastric emptying by modulating gastrointestinal motility via vagal and enteric neural pathways. This effect is characterized by decreased antral contractility, increased pyloric tone, altered gastric accommodation, and longer retention of solid gastric contents [37]. While these physiological changes promote satiety and support weight loss, the same mechanisms also translate into clinically relevant consequences for endoscopic practice: delayed gastric emptying increases the risk that patients will present with retained gastric contents (RGC) despite standard fasting protocols. This mechanistic shift from neural and muscular modulation to delayed solid clearance establishes a direct pathway from drug action to procedural risk, underscoring the need to carefully assess gastric emptying in the peri‐endoscopic management of patients receiving GLP‐1RA therapy. GLP‐1 receptor agonists affect gastric emptying at doses well below those required for glycemic control. Studies with lixisenatide demonstrate marked slowing of gastric emptying independent of glycemic effects, even at low or sub‐therapeutic doses, confirming that gastrointestinal motility effects occur at doses below those required for metabolic control, as shown in controlled physiological studies [44]. This observation has been reinforced in subsequent reviews [17, 25]. This separation between dose and clinical effect is clinically significant and has important implications for peri‐procedural management. Dose reduction alone will likely not prevent gastric stasis in the peri‐procedural setting. These findings support focusing on dietary modification and risk stratification rather than relying solely on changing or stopping medication. Vagal mediation seems fundamental to this response, supported by physiological studies showing reduced GLP‐1–induced gastric stasis after vagotomy [45]. Furthermore, GLP‐1RA‐related changes primarily affect solid‐phase gastric emptying and can lead to retained gastric contents (RGC) despite adherence to standard fasting protocols [21, 22, 32]. Across meta‐analyses and large observational studies, GLP‐1RA exposure is consistently associated with higher rates of RGC and an increased risk of interrupted or aborted upper gastrointestinal endoscopic procedures [18, 46, 47, 48, 49]. Notably, the link between patient‐reported gastrointestinal symptoms and objective gastric retention is weak, limiting the reliability of symptom‐based screening as the sole method for excluding risk [21, 22, 25]. Beyond gastric emptying, GLP‐1RAs may lessen gastric acid secretion and slow down intestinal transit [17, 33]. Reflux symptoms reported during GLP‐1RA therapy probably reflect delayed gastric emptying, gastric distension, and transient lower esophageal sphincter relaxations rather than increased acid exposure [17, 33]. Similarly, cholelithiasis seems more closely linked to rapid weight loss and metabolic changes than to a direct drug‐related effect on motility [50, 51]. Anesthetic Considerations in Patients Taking GLP‐1 Receptor Agonists Undergoing Endoscopy Anesthetic management for gastrointestinal endoscopy aims to optimize procedural conditions while ensuring airway safety. In patients receiving glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), the main challenge is not only medication exposure but also uncertainty regarding residual gastric contents (RGC), particularly solids. Because RGC can occur despite standard fasting and is often asymptomatic, clinicians must consider the possibility of a “full stomach” physiology in selected patients. Consequently, modern peri‐procedural strategies have shifted from uniform medication‐withholding rules to a context‐specific escalation framework that considers procedural factors, sedation depth, airway access, patient vulnerability, and, where available, objective gastric assessment. Sedation Spectrum and Airway Risk Sedation for endoscopy ranges from minimal or moderate sedation to deep sedation and general anesthesia. Deep sedation may suppress airway reflexes and can unpredictably progress to general anesthesia without a secured airway [52]. In many settings (including Australia), deep sedation and non‐intubated general anesthesia are commonly used due to procedural efficiency and favorable recovery profiles; however, these approaches provide limited airway protection and rely on adequate fasting and maintained physiological status [53]. General anesthesia with tracheal intubation offers the best airway protection and ventilatory control, but requires more resources and causes greater physiological disturbance [52]. It is best reserved for situations in which procedural exposure and the risk of physiological aspiration overlap significantly. Conversely, minimal or moderate sedation may reduce the risk of aspiration by preserving protective reflexes. Still, it may be unsuitable for prolonged, complex, or highly stimulating procedures and could compromise procedural tolerance or completion [29]. Upper vs Lower Gastrointestinal Procedures Aspiration risk differs substantially by procedure type: Upper GI Endoscopy (OGD, EUS, ERCP) Upper gastrointestinal procedures involve direct gastric access and a shared airway environment, making RGC clinically significant. Large observational cohorts and pooled analyses demonstrate a higher prevalence of RGC among GLP‐1RA users undergoing upper endoscopy, with reported rates of 8%–20% compared with 3%–6% in non‐users, corresponding to a twofold to fourfold increase and higher rates of interrupted or aborted procedures [18, 21, 22]. This risk seems highest in patients undergoing dose escalation, those with T2DM and autonomic dysfunction, and individuals with additional motility‐impairing factors such as opioid exposure or neurological disease [54]. Despite this robust association between GLP‐1RA exposure and RGC, evidence linking GLP‐1RA exposure to clinically significant aspiration events remains inconsistent. Several large data sets show no increase in aspiration pneumonia compared with matched controls. In contrast, others report a small absolute increase in aspiration‐related outcomes during upper endoscopy, typically occurring in < 0.1%–0.3% of cases, particularly under deep sedation [46, 55, 56, 57, 58, 59]. Importantly, the overall incidence of aspiration remains low. Therefore, the practical implication of GLP‐1RA exposure during upper endoscopy is an increased likelihood of encountering solid gastric residue rather than a predictable rise in aspiration events, guiding proportionate preparation and airway management. The OCULUS trial, the first randomized clinical study to directly address this question, demonstrated that continuing a GLP‐1 or GLP‐1/GIP agonist before elective upper endoscopy resulted in clinically significant residual gastric volume in 25% of patients, compared with 3.1% in those who withheld one dose (absolute difference 21.9%; p = 0.003) [60]. In contrast, among patients who also underwent colonoscopy and adhered to a clear liquid diet the day prior, no clinically significant residual gastric volume was observed, regardless of whether the medication was withheld or continued. These findings indicate that adherence to a clear liquid diet before endoscopic procedures is more effective at reducing the risk of residual gastric volume than withholding a medication dose. These findings should be interpreted in the context of the pharmacokinetic considerations discussed above. The long half‐lives of once‐weekly agents mean that omitting a single dose reduces plasma concentrations by only approximately 50%, and the drug therefore remains substantially active at the time of the procedure. Withholding alone cannot be relied upon to fully restore normal gastric emptying. However, the OCULUS findings suggest that even this partial pharmacokinetic reduction during the fasting window may confer clinically meaningful benefit for upper endoscopy, possibly because a modest reduction in drug levels—combined with the fasting period—is sufficient to reduce gastric stasis at the time of the procedure, even without complete drug clearance. Importantly, the pre‐procedural clear liquid diet eliminated clinically significant residual gastric volume entirely, regardless of whether the medication was held or continued. This observation reconciles the apparent tension between pharmacokinetics and clinical outcome: dietary modification is the most reliable and consistent mitigation strategy, while dose holding may provide additional benefit for elective upper endoscopy and should be considered on an individualized basis. This interpretation aligns with the peri‐procedural framework presented in this review, which centers on dietary preparation, risk stratification, and selective objective assessment rather than routine medication cessation. Lower GI Endoscopy (Colonoscopy) A colonoscopy does not involve gastric instrumentation and generally has a lower risk of aspiration. Large population‐based and observational studies have shown no increase in aspiration pneumonia or major respiratory complications among patients receiving GLP‐1RAs undergoing colonoscopy, with aspiration‐related events reported in approximately 0.01%–0.05% of procedures [57, 61]. Nevertheless, the risk of aspiration is not eliminated, as sedation, suppression of airway reflexes, positional changes, and colonic insufflation can promote gastroesophageal reflux. Bowel preparation may reduce gastric residue and may provide some protection during same‐day bidirectional endoscopy; however, it does not eliminate the risk [47, 62]. Overall, current evidence supports standard sedation procedures for colonoscopy in most GLP‐1RA users, unless other high‐risk features are present. When to Escalate to Airway‐Protected General Anesthesia Escalation from sedation to airway‐protected general anesthesia should be considered when procedural exposure—such as upper GI access, therapeutic intervention, or prolonged duration—coincides with physiological risk markers [63, 64, 65]. Factors supporting escalation are summarized in Table 2. This approach prevents unnecessary intubation in patients having low‐risk endoscopy procedures while ensuring appropriate caution in higher‐risk gastrointestinal procedures. Table 2High‐risk “red flags” in GLP‐1RA users (consider POCUS and/or airway protection).DomainHigh‐risk features (“red flags”)Medication‐related Dose‐escalation phase (recent initiation or dose increase)High‐dose regimens or recent change in formulationRecent dose timing close to the procedure (particularly for upper GI procedures) Symptom‐related Nausea or vomitingEarly satietyBloating/abdominal distensionReflux/regurgitation, especially if worseningPoor oral tolerance or recurrent post‐prandial fullness Comorbidity‐related Diabetes with autonomic neuropathy/suspected gastroparesis • Severe obesityObstructive sleep apneaChronic opioid useNeurological disease affecting motility (e.g., Parkinson's disease)Connective tissue disease affecting GI function (e.g., scleroderma)Previous aspiration event or high ASA status Procedure/Anesthesia‐related Upper GI procedures (OGD, EUS, ERCP), especially therapeuticProlonged or highly stimulating procedures (e.g., dilation, EMR, ESD)Deep sedation planned or limited airway rescue accessUncertain fasting adherence or unclear dietary preparation Objective indicators Gastric POCUS showing thick fluid or solid contentPrior endoscopy with retained gastric contents or aborted procedure Abbreviations: GLP‐1RAs, glucagon‐like peptide‐1 receptor agonists; POCUS, point‐of‐care ultrasound.John Wiley & Sons, Ltd. High‐risk “red flags” in GLP‐1RA users (consider POCUS and/or airway protection). Dose‐escalation phase (recent initiation or dose increase)High‐dose regimens or recent change in formulationRecent dose timing close to the procedure (particularly for upper GI procedures) Dose‐escalation phase (recent initiation or dose increase) Dose‐escalation phase (recent initiation or dose increase) High‐dose regimens or recent change in formulation High‐dose regimens or recent change in formulation Recent dose timing close to the procedure (particularly for upper GI procedures) Recent dose timing close to the procedure (particularly for upper GI procedures) Nausea or vomitingEarly satietyBloating/abdominal distensionReflux/regurgitation, especially if worseningPoor oral tolerance or recurrent post‐prandial fullness Nausea or vomiting Nausea or vomiting Early satiety Early satiety Bloating/abdominal distension Bloating/abdominal distension Reflux/regurgitation, especially if worsening Reflux/regurgitation, especially if worsening Poor oral tolerance or recurrent post‐prandial fullness Poor oral tolerance or recurrent post‐prandial fullness Diabetes with autonomic neuropathy/suspected gastroparesis • Severe obesityObstructive sleep apneaChronic opioid useNeurological disease affecting motility (e.g., Parkinson's disease)Connective tissue disease affecting GI function (e.g., scleroderma)Previous aspiration event or high ASA status Diabetes with autonomic neuropathy/suspected gastroparesis • Severe obesity Diabetes with autonomic neuropathy/suspected gastroparesis • Severe obesity Obstructive sleep apnea Obstructive sleep apnea Chronic opioid use Chronic opioid use Neurological disease affecting motility (e.g., Parkinson's disease) Neurological disease affecting motility (e.g., Parkinson's disease) Connective tissue disease affecting GI function (e.g., scleroderma) Connective tissue disease affecting GI function (e.g., scleroderma) Previous aspiration event or high ASA status Previous aspiration event or high ASA status Upper GI procedures (OGD, EUS, ERCP), especially therapeuticProlonged or highly stimulating procedures (e.g., dilation, EMR, ESD)Deep sedation planned or limited airway rescue accessUncertain fasting adherence or unclear dietary preparation Upper GI procedures (OGD, EUS, ERCP), especially therapeutic Upper GI procedures (OGD, EUS, ERCP), especially therapeutic Prolonged or highly stimulating procedures (e.g., dilation, EMR, ESD) Prolonged or highly stimulating procedures (e.g., dilation, EMR, ESD) Deep sedation planned or limited airway rescue access Deep sedation planned or limited airway rescue access Uncertain fasting adherence or unclear dietary preparation Uncertain fasting adherence or unclear dietary preparation Gastric POCUS showing thick fluid or solid contentPrior endoscopy with retained gastric contents or aborted procedure Gastric POCUS showing thick fluid or solid content Gastric POCUS showing thick fluid or solid content Prior endoscopy with retained gastric contents or aborted procedure Prior endoscopy with retained gastric contents or aborted procedure Abbreviations: GLP‐1RAs, glucagon‐like peptide‐1 receptor agonists; POCUS, point‐of‐care ultrasound. Gastric Point‐of‐Care Ultrasound (POCUS) as an Anesthetic Decision Tool When uncertainty exists—particularly before upper gastrointestinal endoscopy—gastric point‐of‐care ultrasound (POCUS) can provide objective bedside assessment of gastric contents, differentiating an empty stomach from clear fluid, thick fluid, or solid material [66]. These findings may inform decisions to proceed with planned sedation, modify the technique, delay the procedure, or escalate to airway‐protected anesthesia. Gastric POCUS is especially valuable in GLP‐1RA users because symptom screening correlates poorly with retained gastric contents (RGC), and fasting duration may not accurately reflect the true gastric state [67]. The technique typically involves visualizing the gastric antrum in the epigastrium using low‐frequency ultrasound [68]. In the right lateral decubitus position, the antrum provides an optimal acoustic window, facilitating improved assessment of gastric content and volume [69]. Validated grading systems demonstrate good correlation between ultrasound findings and gastric volume, allowing aspiration risk to be assessed along a continuum rather than based solely on fasting‐time thresholds [70]. Importantly, even small volumes of solid gastric content may confer substantially higher aspiration risk than larger volumes of clear fluid, a distinction not captured by conventional fasting guidelines [71]. In the context of GLP‐1RA therapy, gastric POCUS is particularly relevant because delayed gastric emptying may persist despite adherence to standard fasting protocols. Case series and observational studies have reported unexpected retained solids at induction of anesthesia or during upper endoscopy, even after prolonged fasting [71, 72, 73]. These observations have contributed to the endorsement of gastric ultrasound by anesthesia societies, including ANZCA and the ASA, as a practical tool for real‐time peri‐procedural risk assessment [29, 74]. In upper GI procedures, such as esophagogastroduodenoscopy (OGD) or endoscopic ultrasound (EUS), POCUS findings may influence sedation depth, airway planning, and the appropriateness of proceeding on the day, particularly in symptomatic patients or those undergoing dose escalation. Although useful, gastric POCUS has limitations. It is operator‐dependent, with performance influenced by training, image acquisition, and interpretation. Obesity, limited acoustic windows, and post‐surgical anatomy may reduce accuracy [75]. Furthermore, while POCUS can reliably identify solids and large fluid volumes, it does not consistently quantify small residues, predict gastric emptying over time, or distinguish pharmacologically induced stasis from mechanical obstruction [71, 75]. Gastric POCUS should therefore be considered an adjunct to, rather than a substitute for, comprehensive clinical judgment. When used selectively, gastric ultrasound may reduce unnecessary cancellations, prevent inappropriate escalation to airway‐protected general anesthesia, and identify patients who genuinely require modified peri‐procedural management. Its incorporation into peri‐endoscopic workflows aligns with contemporary guidance that favors objective risk assessment and multidisciplinary communication over routine medication cessation. Prokinetic agents should be considered in clinical practice. Erythromycin, a motilin receptor agonist, promotes gastric emptying. According to Australian guidelines, erythromycin is recommended as a potential rescue or pre‐procedural intervention for patients with suspected delayed gastric emptying [29]. Although evidence regarding GLP‐1 receptor agonist–induced gastric stasis is limited, erythromycin (200–250 mg intravenously or 125–250 mg orally, administered 30–60 min before the procedure) may be appropriate when gastric point‐of‐care ultrasound (POCUS) demonstrates retained gastric contents or when high‐risk features are present, and the procedure cannot be postponed [29]. Before administration, antibiotic stewardship principles should be followed, and contraindications, including QT interval prolongation and potential drug interactions, should be evaluated. Communication as the Key Risk‐Mitigation Strategy Across major gastroenterology and anesthesia guidelines, multidisciplinary communication—rather than routine medication cessation—has emerged as the primary risk‐mitigation strategy for patients receiving GLP‐1RAs undergoing endoscopy. Structured pre‐procedure communication (e.g., team huddles and checklist‐based workflows) facilitates early identification of procedural, anesthetic, and nursing concerns and supports consistent risk management [76]. While the peri‐procedural framework (Figure 2) provides a structured approach to risk assessment and escalation, its effectiveness depends on consistent communication between the endoscopist, anesthetist, and nursing team. Failures in peri‐procedural safety more commonly arise from breakdowns in information transfer than from a lack of procedural guidance, underscoring the importance of shared situational awareness when managing patients receiving GLP‐1RAs. Peri‐procedural aspiration risk framework in GLP‐1 users. GLP‐1, glucagon‐like peptide‐1. Central to this process is the principle of procedural ownership (Scopemanship), which emphasizes the endoscopist's responsibility to anticipate procedure‐specific risk and ensure that relevant information is explicitly communicated to the multidisciplinary team. Scopemanship extends beyond technical competence to encompass leadership, situational awareness, and proactive communication, fostering a shared mental model of procedural intent, anticipated exposure, and the escalation threshold. In the context of GLP‐1RA use, this includes advanced disclosures of therapeutic intent, expected procedural duration, likelihood of gastric exposure, and tolerance for interruption or modification, rather than reliance on downstream risk detection at the point of sedation or airway compromise. This approach aligns with established non‐technical skills frameworks in endoscopy and has been associated with improvements in patient safety, team functioning, and overall quality of care [77]. Key elements that should be communicated pre‐procedure include: Procedure type and anticipated complexity (diagnostic vs therapeutic; duration; need for dilation, EMR, ESD, ERCP, or EUS).GLP‐1RA agent and dosing details, including timing of the last dose and whether the patient is in a dose‐escalation phase.Symptom burden, particularly nausea, vomiting, bloating, reflux, abdominal distension, or early satiety.Comorbid aspiration or delayed gastric emptying risk factors, including T2DM with autonomic neuropathy, obesity, obstructive sleep apnea, opioid use, and neurological disease.Fasting adherence and dietary preparation, including any liquid‐diet modification.Planned anesthetic strategy, including sedation depth, airway protection, availability of gastric point‐of‐care ultrasound (POCUS), and thresholds for delay or modification. Procedure type and anticipated complexity (diagnostic vs therapeutic; duration; need for dilation, EMR, ESD, ERCP, or EUS). Procedure type and anticipated complexity (diagnostic vs therapeutic; duration; need for dilation, EMR, ESD, ERCP, or EUS). GLP‐1RA agent and dosing details, including timing of the last dose and whether the patient is in a dose‐escalation phase. GLP‐1RA agent and dosing details, including timing of the last dose and whether the patient is in a dose‐escalation phase. Symptom burden, particularly nausea, vomiting, bloating, reflux, abdominal distension, or early satiety. Symptom burden, particularly nausea, vomiting, bloating, reflux, abdominal distension, or early satiety. Comorbid aspiration or delayed gastric emptying risk factors, including T2DM with autonomic neuropathy, obesity, obstructive sleep apnea, opioid use, and neurological disease. Comorbid aspiration or delayed gastric emptying risk factors, including T2DM with autonomic neuropathy, obesity, obstructive sleep apnea, opioid use, and neurological disease. Fasting adherence and dietary preparation, including any liquid‐diet modification. Fasting adherence and dietary preparation, including any liquid‐diet modification. Planned anesthetic strategy, including sedation depth, airway protection, availability of gastric point‐of‐care ultrasound (POCUS), and thresholds for delay or modification. Planned anesthetic strategy, including sedation depth, airway protection, availability of gastric point‐of‐care ultrasound (POCUS), and thresholds for delay or modification. During upper gastrointestinal endoscopy, real‐time coordination among the endoscopist, anesthetist, and nursing team is particularly important because of the shared airway and the potential for unexpectedly retained gastric contents. Post‐procedural documentation and communication of airway events, RGC, procedural interruptions, or escalation decisions are essential for informing planning of future endoscopic procedures. Guideline Recommendations on Peri‐Endoscopic Management of GLP‐1RA Traditional fasting recommendations for endoscopy have largely been extrapolated from anesthesia guidelines (fasting from solids for 6 h and clear fluids for 2 h) [53, 78, 79]. Increasing evidence supports more permissive approaches to clear fluids, with large initiatives (e.g., “Sip ‘til Send”) demonstrating improved patient comfort without increasing aspiration events [80, 81, 82, 83]. However, upper gastrointestinal endoscopy remains a special case in GLP‐1RA users because these agents predominantly impair solid‐phase gastric emptying, and retained solids may persist despite apparently appropriate fasting. As a result, contemporary guidance increasingly favors dietary modification (e.g., a liquid diet) and individualized assessment over prolonged fasting alone. Over the past 3 years, multiple professional societies have issued peri‐procedural guidance on the use of GLP‐1RAs. Recommendations have evolved substantially from early conservative withholding advice toward risk‐stratified continuation policies. Early guidance (e.g., ASA 2023) suggested pre‐procedural withholding, particularly for weekly formulations [74]. As observational evidence has accumulated, demonstrating increased retained gastric contents (RGC) but low absolute aspiration rates, more recent statements have shifted toward the continuation of therapy with dietary modification and selective use of objective assessment. The main guidelines and evidence on the use of GLP‐1RA prior to endoscopy are summarized in Table 3. Table 3Summary of key guidelines and evidence on GLP‐1RA use prior to endoscopy.SourceKey findingsRecommendationsJAMA Intern Med 2026 (OCULUS RCT)Randomized trial comparing continuation vs withholding of GLP‐1/GIP agonists before upper endoscopy. Clinically significant residual gastric volume in 25% (continued) vs 3.1% (withheld). No significant residual gastric volume when a clear liquid diet was used, regardless of drug continuation.Dietary modification (clear liquid diet) is the most effective strategy to reduce residual gastric volume. Withholding a dose may provide additional benefit in selected upper GI procedures, but it is not sufficient aloneJGH 2025 colonoscopy study (n = 253,326)No increased aspiration pneumonia; trend toward reduced risk (RR 0.70); no ↑ ventilation or respiratory failureColonoscopy is safe; no need for restrictive fasting, medication withholding, or pre‐gastroscopyASGE 2025 Position StatementGLP‐1 RAs primarily delay solid emptying; liquid emptying is preservedMandatory 24‐h liquid diet for OGD; do not discontinue therapy; no role for screening gastroscopyANZCA/GESA/ADS/NACOS 2025Absence of symptoms does not predict emptying; cessation has no evidence; fasting guidelines need adaptationDo not withhold therapy; recommend 24‐h clear liquids + 6‐h fast for all endoscopies; consider gastric POCUS if uncertainAGA 2024 Rapid UpdateLimited evidence for aspiration risk; widespread unnecessary cancellations due to misinterpretation of ASA guidanceManagement should be individualized; do not routinely stop GLP‐1 RAs; focus on symptoms and communicationBMJ 2024 cohort (n = 43,365)No increased aspiration risk; higher rate of retained solids during OGD; more incomplete OGDsDo not withhold GLP‐1 RAs; prioritize dietary modificationAbbreviations: GLP‐1, glucagon‐like peptide‐1; GLP‐1RAs, glucagon‐like peptide‐1 receptor agonists; OGD, esophagogastroduodenoscopy.John Wiley & Sons, Ltd. Summary of key guidelines and evidence on GLP‐1RA use prior to endoscopy. Abbreviations: GLP‐1, glucagon‐like peptide‐1; GLP‐1RAs, glucagon‐like peptide‐1 receptor agonists; OGD, esophagogastroduodenoscopy. The AGA 2024 Rapid Clinical Practice Update opposed routine discontinuation, citing a lack of supportive evidence and potential harms, including hyperglycemia, metabolic destabilization, weight rebound, and logistical disruption [28]. The ASGE 2025 statement reinforced this position, recommending a 24‐h liquid diet before upper GI procedures and discouraging pre‐emptive “screening gastroscopy” before colonoscopy, while recognizing the limited predictive value of symptom screening alone [30]. Australian multidisciplinary guidance (ANZCA/GESA/ADS/NACOS, 2025) offers practical endoscopy‐specific recommendations, including a 24‐h clear‐liquid diet with standard fasting prior to elective procedures and strong endorsement of gastric point‐of‐care ultrasound (POCUS) when uncertainty exists [29]. Collectively, guidelines now converge on a consistent principle: GLP‐1RA continuation is appropriate for most patients, with procedural safety optimized through dietary modification, structured risk assessment, selective ultrasound, and multidisciplinary communication rather than routine medication cessation. Peri‐Procedural Framework for GLP‐1RA Users Undergoing Endoscopy The rapid expansion in the use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), together with accumulating evidence linking these agents to gastric stasis and retained gastric contents (RGC), has created a need for a structured, physiology‐informed peri‐procedural framework. Rather than relying on rigid strategies such as routine medication cessation or prolonged fasting, contemporary approaches emphasize personalized risk assessment, dietary preparation, selective use of gastric point‐of‐care ultrasound (POCUS), and coordinated multidisciplinary communication. In practice, procedural risk is driven by the interaction between (i) patient vulnerability to delayed gastric emptying, (ii) GLP‐1RA dosing phase and symptom burden, and (iii) procedural and anesthetic exposure—particularly during upper gastrointestinal endoscopy and deep sedation. Objective assessment using gastric POCUS can clarify uncertainty during sedation/anesthesia and inform proportionate escalation, including procedure modification, delay, or airway‐protected general anesthesia when retained solids are suspected or confirmed. A pragmatic, stepwise framework for pre‐assessment, preparation, and day‐of‐procedure decision‐making is summarized in Figure 2 and key high‐risk “red flag” features are summarized in Table 2. Future Directions and Research Priorities When gastric emptying is formally evaluated—whether in clinical trials or in patients with suspected gastroparesis—scintigraphy remains the gold‐standard technique, providing direct quantification of solid‐ and liquid‐phase emptying [84, 85, 86]. The [13C]‐octanoate or [13C]‐spirulina stable isotope breath test represents a validated, radiation‐free alternative with good correlation to scintigraphic measurements and is increasingly used in clinical research and practice [87, 88]. Despite the rapid increase in GLP‐1RA prescribing across metabolic diseases, the evidence base informing peri‐endoscopic practice remains limited, fragmented, and predominantly retrospective. Consequently, much current guidance relies on expert consensus rather than definitive prospective data. Addressing these gaps will be essential to clarify true aspiration risk, refine patient selection, and support personalized physiology‐based pathways. A key priority is the generation of prospective multicentre data incorporating standardized definitions of aspiration‐related events, structured documentation of fasting adherence and symptoms, and objective assessment of gastric contents using tools such as point‐of‐care ultrasound or scintigraphy. Existing retrospective analyses are constrained by inconsistent definitions of aspiration, limited procedural and anesthetic detail, and reliance on administrative coding, all of which hinder meaningful risk stratification. Randomized trials may be ethically and logistically challenging, given the risk of metabolic destabilization with medication interruption and the safety implications of an altered fasting strategy [89]. Therefore, pragmatic observational designs, particularly nested case‐control analyses within prospective registries, may be the most feasible approach for studying rare aspiration outcomes in real‐world practice. In parallel, validated peri‐procedural risk prediction tools are needed. Such tools should integrate patient‐related variables (e.g., obesity, diabetes‐related autonomic dysfunction, opioid exposure), pharmacological features (agent, timing, dose escalation), procedure‐related factors (gastric access and intervention complexity), and anesthetic parameters (sedation depth, airway difficulty), with incorporation of objective markers such as gastric ultrasound findings. Machine‐learning approaches may accelerate the development of personalized risk models that guide fasting strategies, determine suitability for sedation versus general anesthesia, and set thresholds for delay or airway protection. Pharmacogenomics is another emerging frontier. Variability in gastrointestinal tolerability and delayed gastric emptying suggest that genetic factors influence GLP‐1 signaling sensitivity. Early associations—including GLP1R polymorphisms such as rs6923761—raise the possibility that genetic profiling could eventually identify individuals predisposed to significant gastric stasis, allowing tailored peri‐procedural planning in high‐risk patients [90, 91, 92]. Ultimately, the goal is a precision‐endoscopy pathway that classifies patients not solely by medication status but by integrating clinical, physiological, procedural, and objective assessment factors. Such pathways could reduce unnecessary cancellations, prevent avoidable aspiration events, and improve efficiency as the population of GLP‐1RA users undergoing endoscopy continues to grow. Conclusion GLP‐1RAs are now widely used in the treatment of metabolic diseases, and their effects on gastric emptying have introduced new considerations for peri‐endoscopic care. Although these agents consistently increase the likelihood of retained gastric contents, particularly during upper gastrointestinal endoscopy, current evidence does not demonstrate a substantial increase in clinically significant aspiration. Contemporary guidance therefore favors continuation of GLP‐1RA therapy alongside dietary modification, structured risk assessment, selective use of gastric POCUS, and close multidisciplinary communication. Emerging prospective evidence further supports the role of pre‐procedural dietary preparation and individualized consideration of dose timing for weekly agents in elective upper gastrointestinal endoscopy, complementing rather than replacing current guideline recommendations. As prescribing continues to expand, structured, individualized, and physiology‐based pathways will be essential to maintain procedural safety while avoiding unnecessary cancellations and disruption of effective metabolic therapy. Author Contributions Idea: Puneet Chhabra. Initial Draft: Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Junaid Beig. Graphics: Jason Ta, Frances Osler. Anesthesia Literature: Marije Jansen, Khalid Sofi. Literature search: Frances Osler, Jason Ta, Sophie Jones, Emily Scott, Junaid Beig. Final Draft and review: Puneet Chhabra, Junaid Beig. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Use of Large Language Models, AI, and Machine Learning Tools We used a large language model (ChatGPT, OpenAI, etc.) to assist with language refinement and manuscript organization. The model was not used for data analysis, interpretation, or the generation of scientific content. All information was independently verified against primary sources, and the authors take full responsibility for the accuracy and integrity of the manuscript.